If BOT net ONLY 1% of US diagnosed sufferers Sales Revenue will exceed half a billion dollars.(@7200p.a. per patient) Simply Wall St value the stock at $8.15 which I'm very happy with but its over the top in my books. $1 is reasonable and concurs with many analysts.
Obviously we're a ways off for $8.15, but it's by no means impossible!
Back in 2016, our Vinnie sold Anacor to Pfizer for US$5.2b (~AUD$8b) on the strength of their product Crisabole selling between $500m and $2b peak sales. BOT making US$500m/year could easily see our share price sitting around the $4 mark, and that could be as quick as only a few years. Give it another couple, plus sales from other products (either bought or pipeline developed) and it is not hard to imagine +$8. NB: The above numbers do take into account that Anacor had only about 53m SOI.
BOT Price at posting:
39.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)